AstraZeneca Pharma India Ltd stock PB Ratio (=24.08) is close to 2-year low of 21.91.
The historical rank and industry rank for AstraZeneca Pharma India's PB Ratio or its related term are showing as below:
NSE:ASTRAZEN'
s PB Ratio Range Over the Past 10 Years
Min: 9.76 Med: 17.72 Max: 34.16
Current: 23.96
During the past 13 years, AstraZeneca Pharma India's highest PB Ratio was 34.16. The lowest was 9.76. And the median was 17.72.
NSE:ASTRAZEN's PB Ratio is ranked worse than 98.05% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:ASTRAZEN: 23.96
During the past 12 months, AstraZeneca Pharma India's average Book Value Per Share Growth Rate was 13.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of AstraZeneca Pharma India was 26.80% per year. The lowest was -11.60% per year. And the median was 14.30% per year.
Back to Basics: PB Ratio
AstraZeneca Pharma India (NSE:ASTRAZEN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's PB Ratio distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a PB Ratio of 24.03 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AstraZeneca Pharma India and its competitors. This is 36% above median its historical median of 17.72. Over the past decade, AstraZeneca Pharma India's PB Ratio has ranged from 9.76 to 34.16. According to the industry distribution chart, AstraZeneca Pharma India ranks #904 out of 922 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is AstraZeneca Pharma India's PB Ratio too high?
AstraZeneca Pharma India's current PB Ratio of 24.03 is 36% above median its 10-year median of 17.72. Over the past 10 years, this metric has ranged from a low of 9.76 to a high of 34.16. The Drug Manufacturers industry median PB Ratio is 1.83. AstraZeneca Pharma India's value of 24.03 is 1216.7% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #904 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #904 out of 922 companies for PB Ratio. This places AstraZeneca Pharma India in the lower half of its industry. The industry median PB Ratio is 1.83. AstraZeneca Pharma India's value of 24.03 is 1216.7% above this benchmark. Historically, AstraZeneca Pharma India's own PB Ratio has ranged from 9.76 to 34.16 over the past decade. While the company's 10-year median is 17.72 vs. the industry median of 1.83, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current PB Ratio of 24.03 is 1216.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current PB Ratio is 24.03, which is 36% above median its own 10-year median of 17.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,868.58, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current PB Ratio is 24.03, which is 36% above median its 10-year median of 17.72 and 1216.7% above the Drug Manufacturers industry median of 1.83. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current PB Ratio is 24.03 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,868.58.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
PB Ratio: 24.03 (36% above median its 10-year median of 17.72)
GF Value™: ₹10,868.58 vs. price of ₹8,391.00 (22.8% below fair value)
Industry Position: 1216.7% above the Drug Manufacturers median (#904 of 922)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
